Navigation Links
Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
Date:8/3/2010

ch which may include a combination of behavior modification and pharmacotherapy," said Thomas Wadden, Ph.D., lead investigator and Professor of Psychology in Psychiatry at the University of Pennsylvania School of Medicine and Director of the Center for Weight and Eating Disorders.  "This study clearly demonstrates that when Contrave is added to a state of the art diet and exercise regimen, patients can achieve significant incremental weight loss."  

Results showed that the addition of Contrave to intensive behavior modification was also associated with statistically significant greater improvements in markers of cardiometabolic risk, including waist circumference, triglycerides, high density lipoprotein (HDL) cholesterol and fasting insulin.  The most common adverse events included nausea, headache, constipation and dizziness.  Observed adverse events were, in general, consistent with the other studies within the COR program and with the safety profile of the constituent components.

"Medication alone may not be the answer for the majority of obese patients, so it's important that we understand the benefits of a multi-modal weight loss program," said Michael Narachi, CEO of Orexigen.  "The results from this study reinforce our belief that a weight management strategy, addressing both the biological and behavioral drivers of obesity, can be successful."

Study Design

COR-BMOD was a 56-week placebo-controlled, double-blind, randomized trial that enrolled overweight and obese adults.  A total of 793 patients were randomized to receive either Contrave32 + BMOD or placebo + BMOD in a 3:1 ratio.  Nine sites in the United States participated in the study.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
2. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
3. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
4. Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept
5. Cornerstone Therapeutics Announces Collaboration with The Cough Company
6. Hepatitis C Therapeutics Market - Taiwan
7. Amicus Therapeutics to Host Its Second Quarter 2010 Financial Results Conference Call and Webcast on August 5, 2010
8. Abviva Announces Notice of Canadian Patent for Technology Used in Breast Cancer Diagnostics and Therapeutics
9. MabVax Therapeutics Initiates Phase II Clinical Trial of Vaccine to Prevent Recurrent Sarcoma
10. Cornerstone Therapeutics to Host Second Quarter 2010 Conference Call
11. Richard B. Brewer Joins Nile Therapeutics as Executive Chairman of the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... named the 2013 Life Science Firm of the Year by ... Vanda was honored at the TCM,s 25 th Annual ... Maryland.  The Tech Awards Celebration recognizes the leaders and innovators ... Maryland and the surrounding regions. ...
(Date:5/23/2013)... de mayo de 2013  Volcano Corporation (NASDAQ: ... fabricante de herramientas de precisión para terapia guiadas ... la enfermedad vascular periférica y coronaria, anunció hoy ... enosine V asodilator I ndependent ... sesión de ensayo clínico hot line late breaking ...
(Date:5/23/2013)... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... and Chief Executive Officer of Neurocrine Biosciences, will be presenting ... Care Conference in Boston.   The live presentation ... Time / 8:20 a.m. Pacific Time.  The presentation will be ... http://www.neurocrine.com . If you are unable ...
Breaking Medicine Technology:Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... (CRL) has invested in a low-dose, state-of-the-art CT machine ... Minnesota.  This advanced diagnostic system will help physicians reach ... care with a radiation dose up to 40% lower ... "The addition of the GE Healthcare Brightspeed Elite CT ...
... ECRI Institute ®, an independent ... improving patient care, today announces the launch of its ... to ECRI Institute,s SELECTplus™ healthcare technology advisory service. The ... intelligence to help hospitals and health systems select and ...
Cached Medicine Technology:Consulting Radiologists, Ltd. Announces Addition of a Low Dose Advanced Computed Tomography (CT) System 2ECRI Institute Launches Market Analytics Tool to Help Hospitals Make More Informed Capital Purchasing Decisions 2ECRI Institute Launches Market Analytics Tool to Help Hospitals Make More Informed Capital Purchasing Decisions 3
(Date:5/23/2013)... Science published an article about bexarotene as a ... starting point for further Alzheimer,s research. The research group ... and KU Leuven in collaboration with the group ... at Janssen Pharmaceutica, Beerse, also tested this candidate drug ... different, as were those of two American study groups. ...
(Date:5/23/2013)... being dragged to its destruction inside a cell, ... signals that thwart the development of tumor-suppressing microRNAs ... early online publication at Nature . , ... tumors, the epidermal growth factor receptor (EGFR) gums ... led by scientists at The University of Texas ...
(Date:5/23/2013)... 23, 2013 The Rottenstein Law Group ... has created the Tylenol Lawsuit Information Center at ... users and those who are considering filing lawsuits. ... potentially cause severe liver damage, according to a 2009 ... In the “safety communication,” the FDA warned consumers against ...
(Date:5/23/2013)... DC (PRWEB) May 23, 2013 The ... a great deal of control over their level of ... weight, yet far fewer are actually taking that control. ... Food Information Council (IFIC) Foundation’s 2013 Food & Health ... respondents say it’s possible to have “a great deal ...
(Date:5/23/2013)... Jeanne Ettelson, president of Beyond OCD , ... free OCD support group in Chicago. Launched in ... the group is lead by psychologists who specialize in ... group participants to learn accurate information about OCD, Cognitive ... in Beyond OCD’s support group benefit from being ...
Breaking Medicine News(10 mins):Health News:New insights contradict promising Alzheimer's research 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 3Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 4Health News:Beyond OCD Support Group Marks Fifth Anniversary 2
... by youngsters with the disease , THURSDAY, July 2 (HealthDay ... to be overweight than those without the disease, increasing their ... is from a major study that explored the weight problems ... common form of the disease that usually shows up in ...
... the launch of (RED)ZONES at the first U2 360 Degrees concert ... rapturous sold out crowd of 90,000 fans. , , ... will be present throughout the U2 tour. The tickets for ... the ticket sales going to the Global Fund to help fund ...
... reports of DEA intervention are accurate, Michael Jackson,s doctors will ... won,t end there. The pharmacists who filled Mr. Jackson,s prescriptions ... name is associated with any of Jackson,s prescriptions," said attorney ... won full federal jury acquittal at trial on a 10 ...
... Cardinal Health today announced that Bruce L. Downey will ... of the planned spinoff of CareFusion Corporation, replacing John B. ... after 22 years of service to the company as a ... chairman and chief executive officer of Barr Pharmaceuticals, Inc. and ...
... the advisory committee,s recommendations to the U.S. Food and Drug Administration (FDA) ... physician leaders from the American Academy of Pain Medicine ... The American Academy of Pain Medicine ... specialty of Pain Medicine, supports the safe and responsible, ...
... the pipeline, could plug a Percocet-Vicodin gap, experts say, , ... Percocet and Vicodin, which a U.S. health advisory panel has ... medical experts contend. , The reason, they say, is that ... Administration advisory panel made its recommendation Tuesday. It followed the ...
Cached Medicine News:Health News:Kids With Type 1 Diabetes Often Overweight 2Health News:(RED)ZONES Launch at First U2 360 Degrees Concert in Barcelona 2Health News:(RED)ZONES Launch at First U2 360 Degrees Concert in Barcelona 3Health News:DEA Will Play Hardball in Investigating Michael Jackson's Doctors 2Health News:Cardinal Health Appoints Bruce Downey to Board of Directors; John McCoy Retires From Board After 22 Years 2Health News:Pain Medicine Experts Recommend Safe and Responsible Use of Acetaminophen 2Health News:If 2 Painkillers Are Banned, What Next? 2Health News:If 2 Painkillers Are Banned, What Next? 3Health News:If 2 Painkillers Are Banned, What Next? 4
... The Series I Instrument program offers ... low profile, while maintaining strength and durability. ... pathology in tight joint spaces. Series I ... cutting tip style, size and angle required ...
... I Instrument program offers state-of-the-art quality in ... maintaining strength and durability. Low profile cutting ... joint spaces. Series I instruments are available ... size and angle required for large and ...
... Punch series facilitates fast and effective resection ... anatomically shaped meniscal rim. The flat, crescent-shaped ... access even the tightest joint spaces. Made ... 20 years of engineering experience in arthroscopy ...
... Punch series facilitates fast and effective resection ... anatomically shaped meniscal rim. The flat, crescent-shaped ... access even the tightest joint spaces. Made ... 20 years of engineering experience in arthroscopy ...
Medicine Products: